Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer: The Multicenter Intergroup Study DESKTOP II. A Project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO

Abstract

This score is the first prospectively validated instrument to positively predict surgical outcome in recurrent ovarian cancer. It can aid in the selection of patients who might benefit from secondary cytoreductive surgery and will be enrolled in the recently started randomized prospective DESKTOP III trial investigating the role of surgery in recurrent platinum-sensitive ovarian cancer.

Total or Subtotal Colectomy in Patients Undergoing Surgery for Primary or Recurrent Epithelial Ovarian Cancer

“…In the recurrent setting, if certain eligibility criteria like ascites below 500 ml, good performance status, and no residual tumor after primary surgery are met [15,16], a secondary cytoreductive surgery is also associated with significantly improved progression-free and overall survival [17,18]. Hyperthermic intraoperative chemotherapy is also a feasible option in platin-sensitive recurrence [19], survival benefit is being evaluated in ongoing prospective trials [20].…”

Phase II study of interval debulking surgery followed by intraperitoneal chemotherapy for advanced ovarian cancer: A Kansai Clinical Oncology Group study (KCOG9812)

“…Complete cytoreduction with no residual tumor was the predictor of improved survival for IDS, and defined as "optimal surgery" [16]. Several reports have shown that complete resection at recurrence leads to improved survival [37], and Harter et al, verified that primary optimal surgery was a predictive factor for successful surgery at recurrence [38]. We treated patients who had microscopic residual tumors in the pelvic peritoneum obtained during IDS.…”

Surgical management of recurrent ovarian cancer

“…There were several additional prognostic factors studied in other small series: complete clinical response to platinum primary chemotherapy, GOG or ECOG performance status, absence of ascites, size of largest tumor b10 cm, number of recurrence sites 1 or 2 versus ≥3, no salvage chemotherapy prior to SCS, ≥6 cycles of salvage chemotherapy after SCS, serum CA-125 level ≤ 35 U/mL at SCS, and platelet count b350 × 10 9 /L at SCS [13,19,32,38,[41][42][43].…”